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Background: The incidence of ductal carcinoma in situ (DCIS) has risen dramatically with
the introduction of screening mammography. The aim was to evaluate differences in patho-
logical and biological characteristics between patients with screen-detected and interval DCIS.
Methods: From January 1992 to December 2001, 128 consecutive patients had been treated
for pure DCIS at our institute. From these, 102 had been attending the Dutch breast cancer
screening program. Sufﬁcient parafﬁn-embedded tissue was available in 74 out of the 102 cases
to evaluate biological marker expression (Her2/neu, ER, PR, p53 and cyclin D1) on tissue
microarrays (TMA group). Differences in clinicopathological characteristics and marker
expression between screen-detected and interval patients were evaluated. Screen-detected
DCIS was classiﬁed as DCIS detected by screening mammography, when the two-year earlier
examination failed to reveal an abnormality. Interval patients were classiﬁed as patients with
DCIS detected within the two-year interval between two subsequent screening rounds.
Results: Screen-detected DCIS was related with linear branching and coarse granular
microcalciﬁcations on mammography (p < .001) and with high-grade DCIS according to the
Van Nuys classiﬁcation (p = .025). In univariate analysis, screen-detected DCIS was related
with Her2/neu overexpression (odds ratio [OR] = 6.5; 95%CI 1.3–31.0; p = .020), and
interval DCIS was associated with low-grade (Van Nuys, OR = 7.3; 95% CI 1.6–33.3; p =
.010) and PR positivity (OR = 0.3; 95%CI 0.1–1.0; p = .042). The multivariate analysis
displayed an independent relation of Her2/neu overexpression with screen-detected DCIS (OR
= 12.8; 95%CI 1.6–104.0; p = .018).
Conclusions: These ﬁndings suggest that screen-detected DCIS is biologically more
aggressive than interval DCIS and should not be regarded as overdiagnosis.
Key Words: Breast neoplasm—Ductal carcinoma in situ—Screening—Biological mark-
ers—Immunohistochemistry.
With the introduction of widespread screening
mammography, the incidence rates of ductal carci-
noma in situ (DCIS) have risen dramatically in
Western Europe and North America.1–3 DCIS now
accounts for nearly 20% of all screen-detected breast
malignancies.4
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As a consequence, treating physicians are con-
fronted with a cumulative caseload because it is not
known how many women with screen-detected DCIS
will develop an invasive carcinoma in their lifetimes.
The proportion of untreated cases of DCIS that
would progress to invasive malignancy has been dif-
ﬁcult to evaluate, because DCIS is usually excised
when detected. Because DCIS is a nonobligatory
precursor to invasive carcinoma, and, therefore, has a
relatively benign nature, screen-detected DCIS has
been argued to represent an overdiagnosis.5,6 This
argument is supported by autopsy studies in which
the median prevalence of DCIS was 8.9%, suggesting
some cases do not progress to clinically signiﬁcant
lesions in a patients lifetime.7 On the contrary, pa-
tients with DCIS treated with biopsy alone in the
premammography era had a higher rate of sub-
sequent occurrences (14–50%) of invasive breast
cancer than expected.8,9 Large clinical trials, in which
patients had been treated with lumpectomy alone,
have also indicated that DCIS can recur as invasive
ductal carcinoma.10,11
Screen-detected DCIS is more often presented as
linear branching microcalciﬁcations on mammogra-
phy than symptomatic DCIS.12 The screen-detected
group in the previously mentioned study had a larger
proportion of patients with comedocarcinoma.
Therefore, it was suggested that linear branching
microcalciﬁcations were related with a more aggres-
sive type of DCIS.12 This is conﬁrmed in other re-
ports that have indicated that linear branching
microcalciﬁcations on mammography are associated
with high grade DCIS.13,14
We believe that screen-detected DCIS is more often
associated with suspicious microcalciﬁcations repre-
senting high-grade DCIS, which has been detected
before it has had the chance to progress to invasive
cancer. Therefore, it is hypothesized that screen-de-
tected DCIS is biologically more aggressive than
interval DCIS. To compare screen-detected DCIS
with interval DCIS in such a retrospective study, the
clinicopathological and biological characteristics of
both groups were evaluated for diﬀerences. Screen-
detected DCIS was classiﬁed as DCIS detected by
screening mammography, when the examination
from two years earlier failed to reveal an abnormal-
ity. Interval DCIS was classiﬁed as DCIS detected
within the two-year interval between two subsequent
screening rounds, when the earlier examination failed
to reveal an abnormality. Age, tumor size, and
pathological grade were studied for their known
relation with local recurrence. Finally, the expression
of established prognostic biomarkers in breast cancer
was studied by immunohistochemistry for estrogen
receptor (ER), progesterone receptor (PR), Her2/neu,
p53, and cyclin D1.
PATIENTS AND METHODS
Patients and Tumors
The Dutch screening program for breast cancer has
been gradually implemented in the North Nether-
lands since 1991. It oﬀered biennial mammography to
women 50–69 years old, and since 1999 women 70–74
years old have also been included. Women received
mammography in the cranio-caudal and medio-late-
ro-oblique direction for each breast. Two radiologists
evaluated the mammograms by a double independent
reading.
From January 1992 to December 2001, 128 con-
secutive patients were treated for pure DCIS at our
institution. To identify patients for inclusion in the
study, all women who had actually attended the
screening program at least two subsequent rounds
with a two-year interval at the time of diagnosis were
considered as attenders. Patients who had skipped
one or more screening rounds previous to the diag-
nosis and patients who had not been attending the
program at all were considered nonattenders. Pa-
tients records were checked to obtain this informa-
tion, and if there was no information regarding the
participation of the screening program at the time of
diagnosis the general practitioner was consulted. Out
of the 128 consecutive patients, 102 attenders and 26
nonattenders could be identiﬁed. For immunohisto-
chemistry, patients were selected on the availability of
suﬃcient paraﬃn-embedded tissue. Thirteen out of
the 26 nonattenders and 74 out of the 102 attenders
remained, respectively, for evaluation of Her2/neu
overexpression, estrogen receptor (ER) expression,
progesterone receptor (PR) expression, p53 expres-
sion, and cyclin D1 expression using tissue micro-
array analysis as part of a project protocol that had
been approved by the medical ethics committee. The
patients in the study-group (n = 74) were divided
into two groups. Patients with DCIS that had been
detected by screening mammography were classiﬁed
as screen-detected patients, when the examination
two years earlier failed to reveal an abnormality (n =
54). Patients with DCIS that had been detected
within the two-year interval between two subsequent
screening rounds were classiﬁed as interval patients,
when the earlier examination failed to reveal an
abnormality (n = 20).
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Mammography and Pathological Assessment
Mammographic and pathological characteristics
were derived from mammography and pathological
reports, respectively. Data were delivered and evalu-
ated anonymously. If data were missing, mammog-
raphy and pathological slides were reevaluated.
Mammographic appearances were scored as micro-
calciﬁcations, a mass, a combination of the two, or as
occult. Microcalciﬁcations were scored as ﬁne gran-
ular, coarse granular, or as linear branching. Patho-
logical size had been estimated, and the grade had
been scored according to the European Pathologists
Working Group (EPWG15) and according to the Van
Nuys classiﬁcation.16
Tissue Microarray Construction
Slides from all blocks were evaluated for repre-
sentative areas with DCIS, and tissue microarrays
were prepared as described earlier.17 In brief, the
most representative area of DCIS was marked on the
original hematoxylin and eosin (H&E) stained sec-
tion. With this marked section as an orientation,
three 0.6-mm punches were taken from the selected
area in the donor blocks and mounted in a recipient
block containing approximately 110 biopsies, using a
manual tissue microarray device (Beecher Instru-
ments, Silver Springs, MD). The presence of DCIS in
the arrayed samples was veriﬁed on hematoxylin
eosin stained sections.
Immunohistochemistry
For immunohistochemistry, 3 lm sections of the
paraﬃn-embedded tissue arrays were deparaﬃnized
in 2 changes of xylene for 5 minutes each and grad-
ually rehydrated through changes of graded ethanol
from 100% to distilled water. Antigen retrieval
methods and antibodies are summarized in Table 1.
The endogenous peroxidase reaction was blocked by
incubating the sections in 3% perhydrol for 30 min-
utes. Primary antibodies were diluted in phosphate-
buffered saline (PBS) containing 1% bovine serum
albumin and incubated at room temperature for 1
hour. Samples were then washed in PBS and incu-
bated with secondary and tertiary antibodies. For
visualization of the antibody-antigen complex, the
diaminobenzidine tetrahydrochloride/peroxidase
reaction was used. After a ﬁnal wash with distilled
water, sections were counterstained with hematoxy-
lin. Sections were dehydrated through rising con-
centrations of ethanol and mounted.
Immunohistochemistry was successful in 81/87 cases
for Her2/neu staining, 73/87 cases for ER staining,
71/87 for PR and cyclin D1 staining, and 70/87 for
p53 staining.
Evaluation of Immunohistochemical Staining
All slides stained for molecular markers were read
by two authors (MdR and BvdV). The slides were
randomly reviewed by a third author (JW) and in
case of disagreement between the other two authors.
ER, PR, and p53 were graded based on the percent-
age of cells showing positive nuclear staining in the
ducts with DCIS. ER and PR were considered posi-
tive if nuclear staining was present in ‡10% of the
cases, and p53 was considered positive in case of a
substantial percentage of positively stained nuclei
(>30%). Her2/neu expression was graded as recom-
mended by the HercepTestTM scoring guidelines: 0:
no staining at all or membrane staining in <10% of
tumor cells; 1+: a faint/barely perceptible partial
membrane staining in >10% of the tumor cells; 2+:
weak to moderate complete membrane staining in
>10% of tumor cells; 3+: strong complete mem-
brane staining in >10%. Her-2/neu was considered to
be overexpressed if the score was 3+. Cyclin D1
expression was scored using a semiquantitative sys-
tem as described by Vos et al.18 This system was
based on the staining intensity scored as 0 (none),
TABLE 1. Antigen retrieval methods and antibodies





ER 6F11 Ventana a Tris/HCL 0.1M (pH 9.5) 30 98C microwave RAMBIO Dako SARBIO Dako
PR 1A6 Ventana a Tris/HCL 0.1M (pH 9.5) 30 98C microwave RAMBIO Dako SARBIO Dako
Her-2/Neu CB11 Ventana a Tris/HCL 0.1M (pH 9.5) 30 98C microwave RAMBIO Dako SARBIO Dako
p53 BP-53-12-1 Biogenix 1:800 Tris/HCL 0.1M (pH 9.5) 30 98C microwave RAMBIO Dako SARBIO Dako
Cyclin D1 SP4 Neomarkers 1:50 Tris/HCL 0.1M (pH 9.5) 30 98C microwave RAMBIO Dako SARBIO Dako
a Prediluted by supplier.
ER, estrogen receptor; PR, progesterone receptor;; RAMBIO, rabbit anti-mouse biotin; SARBIO, swine anti-rabbit biotin.
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1 (weak), 2 (moderate), and 3 (strong), and the per-
centage of positive tumor cell nuclei scored as 0 (0%),
1 (1–25%), 2 (25–50%), 3 (50–75%), and 4 (>75%).
The cyclin D1 staining score was calculated as the
sum of the intensity and the percentage of positive
tumor cells.
Statistical Analysis
Diﬀerences in clinicopathological characteristics
between screen-detected and interval patients with
DCIS in the study group, and between the study
group and the excluded group of patients were ana-
lyzed by chi-square analysis. Diﬀerences in clinico-
pathological and biological characteristics between
the study group and the nonattenders were also
analyzed by chi-square analysis. Diﬀerences in age
were tested by using the Mann-Whitney U test.
Univariate analyses, investigating diﬀerences in
pathological and biological features, was performed
by logistic regression, using screen detection as a
dependent variable. Multivariate analyses were per-
formed with a logistic-regression model. The elimi-
nation of variables in a stepwise manner identiﬁed the
statistically signiﬁcant pathological and biological
parameters. A p value of £.050 was considered as
signiﬁcant. All calculations were performed with
SPSS 12.01 (SPSS inc., Chicago, IL).
RESULTS
Table 2 shows the clinicopathological characteris-
tics of the patients in the study group (n = 74).
Screen-detected DCIS was less often symptomatic
than interval DCIS (p < .001). Five patients (25%) in
the interval group had no objective signs on presen-
tation; all patients had felt a lump in the breast that
could not be veriﬁed on clinical examination. On
mammography, microcalciﬁcations were more often
seen in screen-detected DCIS (p = .002). Screen-de-
tected DCIS was more often presented as linear
branching (44.9%) and coarse granular (55.9%) mic-
rocalciﬁcations than interval DCIS (p<0.001). High-
grade DCIS (Van Nuys, 53.1%, p = .025) was also
more often observed in screen-detected DCIS.
Diﬀerences in clinicopathological characteristics
between the study-group (n = 74) and the group of
patients that had been excluded (n = 28) because of
insuﬃcient paraﬃn embedded tissue are outlined in
Table 3. There was no marked difference in age,
microcalciﬁcations, tumor size, and pathological
grade according to the EPWG classiﬁcation between
both groups. The excluded group of patients repre-
sented a relatively large proportion of low-grade
DCIS according to the Van Nuys classiﬁcation (p <
.001) in comparison with the TMA group.
There were no diﬀerences in clinicopathological
and biological characteristics between the study group
and the nonattenders (n = 13), except the fact that
nonattenders were younger than the patients in the
study group (55.9 years versus 59.6 years; p = .042).
Table 4 displays the relation among pathological
characteristics, biological marker expression, and
mode of detection in the study group. Univariate
logistic regression analysis indicated that in screen-
detected DCIS Her2/neu is more often overexpressed
(odds ratio [OR] = 6.5; 95% conﬁdence interval [CI]
1.3–31.0; p = .020). Interval DCIS is more frequently
TABLE 2. Clinicopathological characteristics of the
patients in the study group and differences between






n = 20 p-valuea
Age (mean), years 58.9 60.7 .187
Family history of breast cancer .055
Yes 8 (14.8) 7 (35)
No 46 (85.2) 13 (65)
Signs
Palpable mass 5 (9.3) 6 (30) <.001
Nipple discharge 2 (3.7) 9 (45)
Mastodynia 1 (1.9) 0 (0)
No objective signs 46 (85.1) 5 (25)
Mammography .002
Microcalciﬁcations 46 (85.2) 10 (50)
Mass 2 (3.7) 6 (30)
Combination mcs and mass 6 (11.1) 4 (20)
Microcalciﬁcations <.001
Linear branching 22 (44.9) 4 (28.6)
Coarse granular 27 (55.1) 4 (28.6)
Fine granular 0 (0) 6 (42.9)
Mammographic size .183
£2 cm 21 (42.6) 12 (60)
>2 cm 33 (57.4) 8 (40)
BCS 23 (42.6) 8 (40) .841
Mastectomy 31 (57.4) 12 (60)
Tumor size .787
<16mm 19 (35.2) 6 (30)
16–40mm 17 (31.5) 8 (40)
>40 mm 18 (33.3) 6 (30)
Grade (EPWG) .229
1 4 (7.5) 4 (20)
2 29 (53.7) 11 (55)
3 21 (38.9) 5 (25)
Grade (Van Nuys) .025
1 4 (7.4) 6 (30)
2 24 (44.4) 9 (45)
3 26 (53.1) 5 (25)
Mann-Whitney U test.
Values between parentheses are percentages.
BCS, breast conserving surgery; EPWG, European Pathologist
Working Group.
a Chi-square analyses.
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positive for PR staining (OR = 0.3; 95% CI 0.1–1.0;
p = .042) and is related to low pathological grade
according to the Van Nuys classification (OR = 7.3;
95% CI 1.6–33.3; p = .010). In multivariate logistic
regression, including pathological grade according to
the EPWG and Van Nuys classification, Her2/neu
overexpression and PR expression in the model,
Her2/neu overexpression was the only independent
indicator for screen-detected DCIS (OR = 12.8; 95%
CI 1.6–104.0; p = .018).
DISCUSSION
Approximately 1 in every 1300 screening mam-
mography examinations leads to a diagnosis of
DCIS.4 Data from a large trial and service screening
programs in the United Kingdom, the Netherlands,
Australia, and the United States have demonstrated
that a woman attending prevalence screen has a 19
times greater chance of having a progressive DCIS or
an invasive tumor diagnosed than of having a non-
progressive DCIS diagnosed.19 It is questioned what
to do with the high detection rate of screen-detected
DCIS. It was hypothesized that screen-detected DCIS
is biologically more aggressive than interval DCIS
because suspicious microcalciﬁcations, detected by
the screening program, will probably more frequently
represent high-grade DCIS. Therefore screen-de-
tected DCIS was characterized pathologically and
biologically to determine whether screen-detected
DCIS differed from interval DCIS. The results of this
study indicate that screen-detected DCIS is patho-
logically (OR = 7.3; 95% CI 1.6–33.3; p = .010) and
biologically (OR = 12.8; 95%CI 1.6–104.0; p = .018)
more aggressive than interval DCIS. Indeed screen-
detected DCIS was related with more suspicious
microcalcifications (p < .001). DCIS detected by a
prevalence screen was pathologically and biologically
comparable to DCIS detected in later rounds (data
not shown) suggesting prevalence and incident cases
to both be of clinical relevance.
The relative incidence of high-grade DCIS in our
series of screen-detected patients was 53%, which is
comparable to the incidence of high-grade DCIS in a
screening population from the Netherlands Cancer
Institute (47%).20 Much data point out that poorly
differentiated or high-grade DCIS lesions have a
greater potential to progress to invasive disease than
low-grade DCIS.21 High grade is also an independent
risk factor of local recurrence after lumpectomy for
DCIS, and approximately 50% of these recurrences
are invasive cancers.22,23 There are no studies avail-
able comparing screen-detected with interval DCIS in
a group of patients that had all been attending the
screening program. Reports on screen-detected DCIS
regarding histopathological grade vary markedly
describing a higher incidence of low grade,24 no dif-
ference,25 or a higher incidence of high grade12,26,27 in
screen-detected DCIS. In these reports screen-de-
tected DCIS is compared to symptomatic DCIS or to
DCIS detected in a period before the screening pro-
gram was introduced. In the present study, a higher
incidence of high-grade lesions, which were classiﬁed
according Van Nuys (OR = 7.3; 95% CI 1.6–33.3; p
= .010) classification, was found in screen-detected
DCIS, indicating a higher malignant potential in
screen-detected DCIS. These results are consistent
with the results from the studies of Evans et al.26 and
Kessar et al.27
DCIS lesions from patients in the study group were
compared to DCIS lesions from patients who had not
attended the screening program. Out of the 26 non-
attenders, there were only 13 patients from whom
suﬃcient paraﬃn-embedded tissue was available.
Using chi-square analysis there were no diﬀerences in
pathological and biological characteristics between
the two groups. The diﬀerence in age could be ex-
plained by the fact that the nonattenders group also
contained patients under 50-years of age. From these
analyses it seems that DCIS in nonattenders is
not pathologically and biologically more aggressive
than DCIS in attenders of the screening program.
TABLE 3. Comparison of clinicopathological characteristics
between the study group and the group of patients that were






n = 28 p-valuea
Age (mean) 59.6 61.5 .381
Microcalciﬁcations (n = 86) .063
Linear branching 26 (41.3) 5 (25)
Coarse granular 31 (49.2) 9 (45)
Fine granular 6 (9.5) 6 (30)
Tumor size .458
<16mm 25 (33.8) 7 (25)
16–40mm 25 (33.8) 9 (32.1)
>40 mm 24 (32.6) 12 (42.9)
Grade (EPWG) .184
1 8 (10.8) 6 (21.4)
2 40 (54.1) 10 (35.7)
3 26 (35.1) 12 (42.9)
Grade (Van Nuys) <.001
1 10 (13.5) 15 (53.6)
2 33 (44.6) 6 (21.4)
3 31 (41.9) 7 (25)
Mann-Whitney U test.
Values between parentheses are percentages.
EPWG, European Pathologist Working Group.
a Chi-square analyses.
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However, because of the very small number of pa-
tients in the nonattenders group no hard conclusions
can be drawn.
Her2/neu overexpression has been found to corre-
late with various pathologic and biological factors
believed to be associated with more aggressive
behavior; high grade, presence of necrosis, ER and
PR negativity, and overexpression of Ki-67 (indicat-
ing an increased proliferation rate) are features that
are strongly related with Her-2/neu overexpres-
sion.28–30 The report of Walker et al.24 displayed a
Her-2/neu expression of 59% in symptomatic DCIS
and of 42% in mammographically detected DCIS.
Another study by Idvall et al.25 reported no differ-
ence in Her-2/neu expression between DCIS before
and after introduction of mammographic screening.
In this present study Her2/neu overexpression was
the only independent feature to be related with
screen-detected DCIS in multivariate analysis (OR =
12.8; 95%CI 1.6–104.0; p = .018), which indicates a
more aggressive profile of screen-detected DCIS
when compared to interval DCIS.
Although the statistical methods used were uni-
variate and multivariate analysis, the numbers in
both groups are small, which explains the broad 95%
CI. The small numbers are due to the selection of
patients in this study for study period, attendance of
screening rounds, and availability of suﬃcient par-
aﬃn-embedded tissue. Clearly, further studies with
larger populations are needed to elucidate the rela-
tive signiﬁcance of the Her2/neu overexpression in
women with screen-detected DCIS. Although 28 out
of 102 patients were excluded because of lack of
suﬃcient paraﬃn-embedded tissue, there is no reason
to assume that this exclusion results in a signiﬁcant
selection bias. Apart from pathological grade
according to Van Nuys, there were no diﬀerences in
clinicopathological characteristics between the study
group and the group of excluded patients. The group
of excluded patients displayed a relatively large
amount of low-grade DCIS according to Van Nuys
(53.6%, p < .001), which is mainly derived from the
interval group (n = 10, data not shown). If all
patients would have been included the relation of
pathological grade and probably Her2/neu expres-
sion with screen-detected patients would be even
more signiﬁcant. The inclusion of patients that
actually took part in the screening program was
TABLE 4. Univariate analysis of pathological and biological characteristics in screen-detected versus interval DCIS in the
study group
Pathological and biological features Screen-detected n = 54 Interval n = 20 OR by screen-detected 95% CI p-value
Tumor size
<16mm 19 (35.2) 6 (30) 0.8 0.2 0.744
16–40mm 17 (31.5) 8 (40) 1.1 0.2 0.827
>40 mm 18 (33.3) 6 (30) 1
Grade (EPWG)
1 4 (7.5) 4 (20) 3.800 0.5 0.377
2 29 (53.7) 11 (55) 1.703 0.7 0.124
3 21 (38.9) 5 (25) 1
Grade (Van Nuys)
1 4 (7.4) 6 (30) 7.3 1.6
2 24 (44.4) 9 (45) 1.6 0.5 0.416
3 26 (53.1) 5 (25) 1 1.6 0.010
Her2/neu (n = 68)
Positive 29 (60.4) 2 (10) 6.5 1.3–31.0 0.020
Negative 19 (39.6) 18 (90) 1
ER(n = 62)
Positive 33 (75) 16 (88.9) 0.4
Negative 11 (25) 2 (11.1) 1 0.1–1.9 0.236
PR (n = 60)
Positive 18 (42.9) 13 (65) 0.3
Negative 24 (57.1) 5 (35) 1 0.1–1.0 0.042
p53 (n = 60)
Positive 10 (24.4) 4 (21.1) 0.8
Negative 31 (75.6) 15 (78.9) 1 0.2–3.1 0.776
Cyclin D1 (n = 60)
Positive 29 (69.1) 13 (72.2) 0.9 0.3–2.9 0.806
Negative 13 (30.9) 5 (27.8) 1
Univariate analysis using logistic regression.
Figures in parentheses are percentages.
OR, odds ratio; EPWG, European Pathologist Working Group; ER, estrogen receptor; PR, progesterone receptor. 95% CI, 95% conﬁdence
interval.
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necessary to analyze diﬀerences between screen-de-
tected and interval DCIS, which, to our knowledge,
has not been performed previously.
Expression of ER, p53, and cyclin D1 was not re-
lated to screen-detected or interval DCIS. There was,
however, a relation between screen-detected DCIS
and PR negativity in univariate analysis (OR =
0.288; 95%CI 0.087–0.957; p = .042). Other studies
could not demonstrate a relation of screen-detected
DCIS with the expression of the aforementioned
markers.12,24,25 In a review by Boland et al.31 ER and
PR positivity are related to low-grade DCIS, whereas
p53 and cyclin D1 expression are associated with high
grade. The fact that screen-detected DCIS is associ-
ated with PR negativity provides indirect evidence for
the presence of a more aggressive tumor biology.
Obviously, PR expression is related to Her2/neu
expression, because PR expression was not signiﬁcant
in multivariate analysis.
Ultimately, the question is how we should interpret
these ﬁndings. The authors think the results from this
study represent no evidence to alter patient manage-
ment and screening recommendations. Instead, they
should rather be regarded as support of current
clinical practice in DCIS of the breast. They conﬁrm
that every DCIS should be treated until we are able to
identify DCIS that will progress to invasive cancer if
left untreated.
In conclusion, since the advent of screening, the
increased incidence of DCIS has raised concerns
about the possibility of overdiagnosis of DCIS. This
study has shown that screen-detected DCIS has a
more aggressive tumor proﬁle than interval DCIS.
Therefore, screen-detected DCIS should not be re-
garded as an overdiagnosis per se, and every woman
diagnosed with DCIS by mammographic screening
should be treated properly according to existing
guidelines or standards of care.
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